Co-founder Dan Myers Named Non–Executive Chairman Additional Changes to the Executive Team   ATLANTA, November 29, 2018 –Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that the company’s

ATLANTA, November 26, 2018 –Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Health Canada has approved ILUVIEN ® for the treatment of diabetic macular edema (DME).

ATLANTA, GA / ACCESSWIRE / November 9, 2018 /  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, Chief Executive Officer, will be presenting at the following investor

Monday, November 5, 2018 7:45 PM Record Net Revenue of $11.1 Million in Q3 2018; U.S. Net Revenue up 20% Record U.S. End User Demand in Q3 2018 Net Loss and Adjusted EBITDA Loss Continue to Improve ATLANTA, GA / ACCESSWIRE / November 5, 2018 / Alimera Sciences, Inc.

ATLANTA, October 23, 2018 –Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the third quarter ended September 30, 2018, after the close of the

ATLANTA, October 22, 2018 –Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that six posters on ILUVIEN ® will be available during the 2018 Annual Meeting of the American Academy of

"CONTINUOUS MICRODOSING with ILUVIEN: Optimizing the Treatment of Persistent or Recurrent DME" Symposium to be held on Friday ATLANTA , Sept. 17, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in commercialization and development of prescription ophthalmic

ATLANTA , Sept. 13, 2018 /PRNewswire/ --  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that two presentations will be delivered, and one poster presented, on ILUVIEN ® during the 2018

ATLANTA , Sept. 4, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has closed an agreement with Deerfield Management and certain of its affiliates (Deerfield)

ATLANTA , Aug. 29, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers , Chief Executive Officer, will be presenting at the annual